Immunosuppressive Agents

Phase 3Small molecule

MMedeor Therapeutics, Inc.

Immunosuppressive Agents is one of 171 small molecule programs targeting Crohn's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseRecruiting

Rheumatic DiseaseActive, not recruiting

DermatomyositisActive, not recruiting

UveitisActive, not recruiting

Glomerulonephritis Rapidly ProgressiveRecruiting

Crohn DiseaseRecruiting

Type 1 DiabetesActive, not recruiting

Crohn's DiseasePhase 3

Recruiting

Rheumatic DiseasePreclinical

Active, not recruiting

DermatomyositisPreclinical

Active, not recruiting

UveitisPreclinical

Active, not recruiting

Glomerulonephritis Rapidly ProgressivePhase 2

Recruiting

Crohn DiseasePreclinical

Recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

79 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

6 2

Stelara

Johnson & Johnson

Phase 3

1 3

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 4

Tricor

JJagotec

Phase 3

2 5

Diamox

Teva

Phase 2

2 6

Kerendia

Bayer

Phase 2

1 7

Humira

Novartis

Phase 2

1 8

Immunosuppressive Agents

MMedeor Therapeutics, Inc.

Phase 3

1 9

Teplizumab

Sanofi

Phase 3

9 10

Prolia

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Type 1 Diabetes

NCT01909245

Q2 2027

PreclinicalRecruiting

Crohn Disease

NCT05321758

Q1 2028

Phase 2Recruiting

Glomerulonephritis Rapidly Progressive

NCT06047171

Clinical

Trials by Indication[1]

Transplantation2 trials

Human Clinical Trial of Uterine Transplantation in the United Kingdom

Unknown status·WWomb Transplant UK·N/A·NCT02388802·10 enrolled

Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects

Unknown status·—·Phase 1·NCT02416674·10 enrolled

Kidney Transplant1 trial

Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants

Withdrawn·MMedeor Therapeutics, Inc.·Phase 2/3·NCT03605654

Infection1 trial

Immunosuppressants to Postoperative Infection and Death

Unknown status·—··NCT06121804·20,000 enrolled

Type 1 Diabetes1 trial

Islet Cell Transplant for Type 1 Diabetes

Active, not recruiting·—·Phase 2·NCT01909245·10 enrolled

Rheumatic Disease1 trial

Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection

Completed·SSociedad Argentina de Reumatologia··NCT04568421·2,982 enrolled

8 more indications

Allograft1 trial

The Role of B Cells in Kidney Allograft Dysfunction

Completed·LLoma Linda University··NCT02294032·180 enrolled

Crohn's Disease1 trial

InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

Recruiting·—·Phase 3·NCT06059989·158 enrolled

Lupus Nephritis1 trial

Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis

Unknown status·NNanjing University School of Medicine·Phase 3·NCT05863936·15 enrolled

Retinal Disease1 trial

Causes of Visual Loss in Retinal Disease

Unknown status·—··NCT01613963·2,000 enrolled

Dermatomyositis1 trial

Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis

Completed·KKarolinska University Hospital··NCT01813617·72 enrolled

Uveitis1 trial

Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis: A Multicenter, Randomized, Non-inferiority Clinical Trial

Completed·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Preclinical·NCT06310837·128 enrolled

Glomerulonephritis Rapidly Progressive1 trial

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis

Recruiting·AAlentis Therapeutics AG·Phase 2·NCT06047171·80 enrolled

Crohn Disease1 trial

Repeated and Multiple Fecal Microbiota Transplantations Plus Partial Enteral Nutrition as the First-line Treatment in Active Pediatric Crohn's Disease

Recruiting·TTongji Hospital·Preclinical·NCT05321758·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Immunosuppressive Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunosuppressive Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunosuppressive Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medeor Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedeor Therapeutics, Inc.

Immunosuppressive Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q1 2028

Trials by Indication[1]

Transplantation2 trials

Kidney Transplant1 trial

Infection1 trial

Type 1 Diabetes1 trial

Rheumatic Disease1 trial

Allograft1 trial

Crohn's Disease1 trial

Lupus Nephritis1 trial

Retinal Disease1 trial

Dermatomyositis1 trial

Uveitis1 trial

Glomerulonephritis Rapidly Progressive1 trial

Crohn Disease1 trial

References

Drug Info

Quick Facts

Related News